[1]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120-1122.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
　Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(11):1120-1122.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
点击复制

急性冠脉综合征患者提前停服替格瑞洛现象的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年11期
页码:
1120-1122
栏目:
综述
出版日期:
2020-11-25

文章信息/Info

Title:
Premature Ticagrelor Discontinuation in Patients with
文章编号:
202004033
作者:
肖雨尘 赵仙先1 马丽萍1; 2
海军军医大学长海医院心血管内科,上海 200433 ;2. 海军军医大学长海医院临床教学中心,上海 200433)
Author(s):
Acute Coronary Syndrome
XIAO Yuchen1, ZHAO Xianxian1, MA Liping1,2 (1.Department of Cardiology, Changhai Hospital, Naval Military Medical University, Shanghai 200433, China; 2. Changhai Center for Simulation Learning and Innovation, Changhai Hospital, Naval Military Medical University, Shanghai 200433, China)
关键词:
急性冠脉综合征; 替格瑞洛; 双联抗血小板治疗; 提前停药
Keywords:
Acute coronary syndrome; Ticagrelor; Dual antiplatelet therapy; Premature discontinuation
DOI:
10.16806/j.cnki.issn.1004-3934.2020.11.000
摘要:
与氯吡格雷相比，替格瑞洛的药物不良反应（出血、呼吸困难和心律失常等）导致的提前停服替格瑞洛现象，很可能限制替格瑞洛的潜在优势。现综述导致提前停服替格瑞洛相关不良反应的发生率、原因和生物学机制，并提出改善替格瑞洛依从性的相关策略。
Abstract:
Compared with clopidogrel, premature ticagrelor discontinuation caused by adverse drug reactions（bleeding, dyspnea and arrhythmia） is likely to limit the potential advantage of ticagrelor. This paper reviews the incidence, causes and biological mechanisms of adverse reactions that may lead to premature ticagrelor discontinuation, and proposes strategies to improve the compliance of ticagrelor

参考文献/References:

[1] 胡盛寿,高润霖,刘力生,等. 《中国心血管病报告 2018》概要[J]. 中国循环杂志, 2019,34(3):209-220.

[2] Lauffenburger JC,Choudhry NK. A call for a systems-thinking approach to medication adherence:stop blaming the patient[J]. JAMA Intern Med, 2018,178(7):950-951.

[3] 周小琳,何泉. 替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展 [J]. 心血管病学进展,2019,40(5):718-722.

[4] Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2018,39(2):119-177.

[5] Bonaca MP,Braunwald E,Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,373(13):1274-1275.

[6] Bonaca MP,Bhatt DL,Oude Ophuis T,et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events:a secondary analysis of the PEGASUS-TIMI 54 Trial[J]. JAMA Cardiol,2016,1(4):425-432.

[7] Dayoub EJ,Seigerman M,Tuteja S,et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention,2008-2016[J]. JAMA Intern Med,2018,78(7):943-950.

[8] Beigel R,akobishvili Z,Shlomo N,et al. Real-world use of novel P2Y12 inhibitors in patients with acute myocardial infarction:a treatment paradox[J]. Cardiology,2017,136(1):21-28.

[9] Winter MP,von Lewinski D,Wallner M,et al. Incidence,predictors,and prognosis of premature discontinuation or switch of prasugrel or ticagrelor:the ATLANTIS- SWITCH study[J]. Sci Rep,2019,9(1):8194.

[10] Zeymer U,Cully M,Hochadel M. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry[J]. Eur Heart J Cardiovasc Pharmacother,2018,4(4):205- 210.

[11] Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11):1045-1057.

[12] Ortega-Paz L,Brugaletta S,Ariotti S,et al. Adenosine and ticagrelor plasma levels in patients with and without ticagrelor-related dyspnea[J]. Circulation,2018,138(6):646-648.

相似文献/References:

[1]陈艳,综述,袁晋青,等.替格瑞洛临床应用新进展[J].心血管病学进展,2016,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
　CHEN Yan,YUAN Jinqing.The Updates of Ticagrelor Use in Clinical Practice[J].Advances in Cardiovascular Diseases,2016,(11):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
[2]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
　LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(11):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[3]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
　ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(11):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
　LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(11):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
　LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(11):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
　DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(11):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
　XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(11):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[8]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
　 FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(11):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[9]魏倩 梁岩.高敏心肌肌钙蛋白在急性冠脉综合征患者中的临床应用进展[J].心血管病学进展,2021,(5):396.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.003]
[10]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
　ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(11):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[11]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
　ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(11):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[12]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
　CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(11):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[13]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
　ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(11):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
[14]王晓妍 崔炜.替格瑞洛治疗急性冠脉综合征时引起缓慢性心律失常的研究进展[J].心血管病学进展,2021,(7):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]
　WANG Xiaoyan,CUI Wei.Bradyarrhythmia Caused by Ticagrelor in Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(11):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]

更新日期/Last Update: 2021-02-03